logo
  

LeapFrog Enterprises Loss Widens, Shares Down 18%

LeapFrog Enterprises, Inc. (LF) Thursday reported a wider loss for the fourth quarter, hurt largely by a hefty asset impairment charge and lower revenues. Shares of the company plunged over 18 percent in the after-hours trading, following the news.

California-based LeapFrog's loss for the quarter widened to $76.2 million or $1.08 per share from $11.8 million or $0.17 per share last year.

Results for the quarter included asset impairment charge of $36.5 million. Excluding items, adjusted loss for the quarter was $39.7 million or $0.56 per share.

Net sales for the quarter dropped 40 percent to $33.9 million from $56.9 million last year.

Analysts polled by Thomson Reuters estimated loss of $0.21 per share for the quarter. Analysts' estimates typically exclude one-time items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC has announced recalls including utility vehicles or UTVs and snowmobiles, as well as electric wall ovens, spin swivel chairs, toy pinwheels, and children's nightgowns citing various reasons. Augusta, Georgia-based Textron Specialized Vehicles is recalling Prowler Pro and Tracker UTVs citing fire risk, as well as Arctic Cat Model Year 2024... Texas Pecan Co. is recalling various nuts, snack mixes, seeds, and snack sticks in 1 Lb and 8 oz sizes, citing the potential to contain undeclared peanut, tree nuts, soy, milk, sesame, and wheat allergens, according to the U.S. Food and Drug Administration. Automajor General Motors plans to end production of its gasoline-powered Chevrolet Malibu car later this year as it prepares to produce new electric vehicles, reports said. Chevy Malibu, which was launched in 1964, has since been sold more than 10 million in numbers. The Malibu will end its production in November.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT